FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Fate Therapeutics

Status and phase: Enrolling; Phase 1

Conditions: Endometrial Carcinoma; Breast Cancer; Ovarian Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer; Non-Small Cell Lung Cancer

Treatments: Drug: FT836; Drug: Trastuzumab; Drug: Cetuximab; Drug: Paclitaxel

Study type: Interventional

Funder types: Industry

Identifiers

NCT07216105

FT836-101

Details and patient eligibility

About

This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.

Enrollment: 113 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• For all regimens, disease that is not amenable to curative therapy and that has relapsed or progressed following at least one line of prior systemic therapy.

• Evidence of adequate organ function as determined by all of the following:

  • Absolute neutrophil count (ANC) >1000/µL without growth factor support within 7 days prior to start of first study intervention
  • Platelet count ≥75,000/µL without transfusion support within 14 days prior to start of first study intervention
  • Estimated creatinine clearance ≥50 mL/minute by Cockcroft-Gault method or other standard institutional method
  • Total bilirubin ≤1.5 × upper limit of normal (ULN); for participants with documented Gilbert syndrome, total bilirubin must be ≤3 ×ULN
  • Aspartate transaminase (AST) ≤3 × ULN or alanine transaminase (ALT) ≤3 × ULN; in participants with documented liver metastases, AST or ALT ≤5 × ULN
  • Alkaline phosphatase (ALP) ≤2.5 × ULN; in participants with documented liver or bone metastases, ALP ≤5 × ULN
  • Oxygen saturation >90% on room air

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.

• Presence of measurable disease by RECIST, v1.1 assessed within 28 days prior to start of first study intervention.

• Presence of baseline safely accessible lesions of adequate size for on-treatment biopsies (exceptions for lesion size may be granted with medical monitor approval) and participant willingness to undergo protocol prescribed on-treatment biopsies.

Exclusion criteria

• Clinically significant cardiovascular disease including any of the following: uncontrolled/ unstable cardiac arrhythmias, myocardial infarction within 6 months prior to start of first study intervention, unstable angina or congestive heart failure of New York Heart Association (NYHA) Grade 2 or higher, or cardiac ejection fraction <50%.
• Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of fifirst study intervention, whichever is shorter.
• Known active central nervous system (CNS) involvement by malignancy. Participants with prior CNS involvement from their malignancy must have completed effective treatment of their CNS disease with no symptoms of disease in the absence of steroid treatment and at least stable findings on relevant CNS imaging and no evidence of leptomeningeal disease for at least 4 weeks prior to study enrollment.
• Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions within 6 months prior to study enrollment.
• Currently receiving or likely to require systemic immunosuppressive therapy (e.g., prednisone ≥5 mg daily) for any reason from start of first study intervention to Day 29 with the exception of corticosteroids as a premedication for chemotherapy side effects per institutional standard of care or as mandated by the protocol.
• Any history of Grade ≥3 immune-related AE or Grade ≥2 eye toxicity attributed to prior cancer immunotherapy, other than endocrinopathy managed with replacement therapy or asymptomatic elevation of serum amylase or lipase.
• Grade ≥2 peripheral neuropathy limiting instrumental activities of daily living.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

113 participants in 6 patient groups

Regimen A ( FT836)

Experimental group

Description:

Participants receive FT836 monotherapy

Treatment:

Drug: FT836

Regimen B ( Paclitaxel + FT836)

Experimental group

Description:

Participants receive Paclitaxel chemotherapy followed by FT836

Treatment:

Drug: Paclitaxel

Drug: FT836

Regimen C ( Cetuximab + FT836)

Experimental group

Description:

Participants receive FT836 combined with cetuximab

Treatment:

Drug: Cetuximab

Drug: FT836

Regimen D ( Paclitaxel + Cetuximab + FT836)

Experimental group

Description:

Participants receive Paclitaxel chemotherapy followed by FT836 combined with cetuximab

Treatment:

Drug: Cetuximab

Drug: Paclitaxel

Drug: FT836

Regimen E ( Trastuzumab + FT836))

Experimental group

Description:

Participants receive FT836 combined with trastuzumab

Treatment:

Drug: Trastuzumab

Drug: FT836

Regimen F ( Paclitaxel + Trastuzumab + FT836)

Experimental group

Description:

Participants receive Paclitaxel chemotherapy followed by FT836 combined with trastuzumab

Treatment:

Drug: Paclitaxel

Drug: Trastuzumab

Drug: FT836